SciSparc Ltd.
SciSparc Ltd. is a U.S.-listed biopharmaceutical company with operations centered in Tel Aviv, Israel, through its majority-owned subsidiary NeuroThera. Its business focuses on clinical-stage cannabinoid-based drug development for central nervous system disorders, alongside a smaller consumer product activity in hemp seed oil products sold online.
Tilikausi 2024 · muutos edellisvuodesta
Kehitys 2021–2024
Liiketoiminta
Osuus liikevaihdostaDrug candidates based on THC and non-psychoactive CBD for CNS and related disorders.
Hemp seed oil-based products sold through Amazon Marketplace.
Early-stage evaluation of AI, cybersecurity, and related opportunities.
Asiakkaat
SciSparc’s primary end users are patients with central nervous system and neurodevelopmental disorders, with the company’s drug programs directed toward conditions such as Tourette syndrome, Alzheimer’s-related agitation, autism spectrum disorder, and status epilepticus. Its consumer products are sold to retail buyers on Amazon Marketplace, while any AI-related activity is still exploratory and aimed at assessing commercial opportunities rather than serving a defined customer base.
Patients, caregivers, and physicians targeted by SCI-110 and SCI-210 for neurological and neurodevelopmental indications.
Consumers buying hemp seed oil-based products through Amazon Marketplace for wellness use.
Potential partners or targets in AI and cybersecurity that may support future corporate development.
Strategia
SciSparc is focused on advancing its cannabinoid-based pipeline in CNS disorders while continuing to seek development, regulatory, and partnership pathways for its programs. The company has also broadened its strategic lens to include agentic AI and cybersecurity, suggesting a corporate development approach that combines life sciences assets with optionality in adjacent technology areas.
Clinical progress is the core value driver for a development-stage pharmaceutical company.
Regulatory milestones can de-risk programs and improve partnering or financing optionality.
Broadens the company’s strategic pipeline beyond pharmaceuticals and may create new optionality.
Maantiede
The company is organized around operations in Tel Aviv, Israel, while being publicly listed in the United States on Nasdaq. Its pharmaceutical development programs are global in nature because clinical-stage drug assets can be developed and tested across multiple jurisdictions, and its consumer product sales are tied to the Amazon marketplace rather than a single country.
Riskit
SciSparc faces the usual development-stage pharmaceutical risks: clinical failure, regulatory delays, and uncertainty over whether its cannabinoid programs will achieve meaningful efficacy and approvals. The company also has execution risk from operating a small business with multiple initiatives, including consumer products and early-stage technology exploration, which can dilute focus and increase financing dependence.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
SCI-110 and SCI-210 are still investigational and may not prove effective or safe in trials.
Kohdistuu: Drug pipeline value
- Regulatory approval uncertaintyVaikutus: KorkeaTodennäköisyys: Korkea
Drug candidates require successful interactions with health regulators before commercialization.
Kohdistuu: Clinical-stage programs
- Financing dependenceVaikutus: KorkeaTodennäköisyys: Korkea
A small development-stage company typically needs recurring capital to fund trials and operations.
Kohdistuu: Corporate liquidity and dilution
- Marketplace concentrationVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Amazon-based consumer sales depend on a single platform’s policies, ranking, and competition.
Kohdistuu: Hemp seed oil products
- Strategic distractionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Adding AI and cybersecurity initiatives may pull management attention away from core biotech assets.
Kohdistuu: Corporate strategy
Kirjanpito
Harkinnanvaraiset erätClinical-stage drug programs typically expense trial and development costs as incurred, affecting reported losses.
Vaikutus: Measures cash burn tied to SCI-110 and SCI-210
Financing rounds with warrants or equity-linked features can require recurring valuation judgments.
Vaikutus: Can create volatility in non-operating results
SciSparc’s ownership stake in NeuroThera may be affected by new financings and dilution.
Vaikutus: Affects balance sheet carrying value and ownership percentages
Marketplace sales need proper gross-versus-net presentation and timing of transfer to customers.
Vaikutus: Influences reported consumer product revenue and margins
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
NeuroSense Therapeutics Ltd.
NRSNW · Pharmaceutical Preparations
Brainstorm Cell Therapeutics Inc.
BCLI · Biological Products, (No Diagnostic Substances)
IRLAB Therapeutics
IRLAB-A · Health Care
IRLAB Therapeutics is a Swedish biopharmaceutical company focused on discovering and developing novel treatments for Parkinson's disease and other central nervous system (CNS) disorders.
XTL Biopharmaceuticals Ltd
XTLB · Pharmaceutical Preparations
CNS Pharmaceuticals, Inc.
CNSP · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Päivitetty: 28.9.2026